（文章来源：证券日报） 证券日报网讯稳健医疗9月25日在互动平台回答投资者提问时表示，基于对公司未来发展的信心，控股 股东——稳健集团有限公司，在IPO上市解禁后，连续两年自愿延长限售期并出具了《关于自愿延长限 售期的承诺》，前述限售期已于2025年9月16日到期。目前，控股股东表示对公司发展充满信心，坚定 看好"医疗+消费"两大业务板块的发展，控股股东明确表示限售到期后暂无减持计划。若未来控股股东 有计划减持股份，公司将按照法律法规要求，督促股东及时、准确地进行信息披露。 ...

Group 1: Investor Relations Activities - The company conducted a specific investor survey and media interviews on May 29, 2025, attended by representatives from Galaxy Securities, Rongxian Huijin Fund, and China Securities Journal [3][4] Group 2: Sales and Market Performance - The overseas market sales have remained stable this year, with the portable pneumatic massage system receiving widespread attention and positive feedback from global customers [4] - The company plans to enhance the market promotion of the compression boots, leveraging existing sales channels in the massage gun sector [4] Group 3: Product Innovation and Development - Future product innovation strategies include increased investment in "medical + consumer" resources and a focus on rehabilitation medical technology [5] - The company aims to develop more products suitable for the elderly, addressing the growing health needs of this demographic [5] Group 4: Profitability and Product Structure - The gross margin for rehabilitation medical products is 47.86%, while rehabilitation technology products have a gross margin of 37.11%, indicating room for improvement [6] - The company is actively developing new products to enrich its product line [6] Group 5: Investment Projects and Production Capacity - The Chengdu Intelligent Manufacturing Production Base is on track for completion, expected to be accepted in July 2025, which will enhance production capacity and efficiency [7] - The introduction of advanced production equipment and automated lines will lower production costs and improve overall profitability [7] Group 6: Research and Development - R&D expenses are determined by various factors, including company strategy and market demand, rather than a fixed threshold [9] - New products such as the medium-frequency therapy device and portable oxygen machine have received regulatory approval, while others are in development [9]